一线免疫化疗失败后弥漫大B细胞淋巴瘤的临床异质性
本研究基于爱荷华大学/梅奥诊所淋巴瘤卓越研究项目的分子流行病学资源,前瞻性纳入2002至2012年间接受一线蒽环类免疫化疗的1039例弥漫大B细胞淋巴瘤(DLBCL)及原发纵隔B细胞淋巴瘤患者,其中244例复发并再治疗。复发后4年总生存率为28%;103例最终接受自体造血干细胞移植,移植后4年总生存率为51%。初始诊断后12个月以上复发者4年总生存率为47%,而对初始治疗仅短暂或无反应者仅为13%。
要点
- 一线免疫化疗失败后复发/难治DLBCL的4年总生存率为28%。
- 103例接受自体造血干细胞移植者移植后4年总生存率为51%。
- 初始诊断后12个月以上复发者4年总生存率为47%,对初始治疗仅短暂或无反应者仅13%。
核心结论
- 复发或难治性DLBCL的结局按对初始治疗的反应、复发时间及接受自体造血干细胞移植的机会分类后差异显著。
- 作者认为,非对照试验的设计与解读应考虑到复发DLBCL患者的这种异质性。
研究设计与样本
- 研究基于爱荷华大学/梅奥诊所淋巴瘤卓越研究项目的分子流行病学资源,前瞻性纳入新诊断淋巴瘤患者。
- 2002年至2012年间共1039例DLBCL及原发纵隔B细胞淋巴瘤患者接受一线蒽环类免疫化疗,其中244例复发并随后再治疗,纳入本分析。
主要发现
- 全部治疗中,复发后4年总生存率为28%。
- 103例患者最终接受自体造血干细胞移植,移植后4年总生存率为51%。
- 初始诊断后12个月以上复发者4年总生存率为47%,对初始治疗仅短暂或无反应者4年总生存率仅为13%。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to describe the patterns of care and outcomes of diffuse large B cell lymphoma (DLBCL) after failure of front line anthracycline-based immunochemotherapy (IC). Patients with newly diagnosed lymphoma were prospectively enrolled in Molecular Epidemiology Resource (MER) of the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellzence. All DLBCL and primary mediastinal B-cell lymphoma (PMBL) patients treated with front-line anthracycline-based IC were followed for relapse. Patients with relapse on follow-up and subsequently retreated were included in this analysis. 1039 patients received anthracycline-based IC between 2002 and 2012, of which 244 relapsed and were subsequently retreated. Across all therapies, overall survival at 4 years (OS4) from relapse was 28% and 103 patients ultimately underwent autologous haematopoietic cell transplant (autoHCT) with OS4 from autoHCT of 51%. Patients relapsing after 12 months from initial diagnosis had OS4 of 47% but those with a transient or no response to initial therapy had OS4 of only 13%. Outcomes of relapsed or refractory DLBCL differ substantially when categorized by response to initial therapy, timing of relapse and opportunity to undergo autoHCT. The design and interpretation of uncontrolled trials should account for this heterogeneity in patients with relapsed DLBCL.
引用
- Farooq U, Maurer MJ, Thompson CA, et al. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. Br J Haematol. 2017. PMID: 28653407. doi:10.1111/bjh.14813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。